Objectives To evaluate how recurrent COVID-19 infections influence the clinical course of patients with chronic obstructive pulmonary disease (COPD), focusing on moderate-to-severe symptom flare-ups, ...
Readers were most interested in how pulmonary rehabilitation referrals and discharge disposition differ with vs. without use of an inpatient COPD clinical pathway embedded directly into the electronic ...
GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...
Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. Home Smart: Penthouse perch in Seaport SJC allows AG ...
Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma’s new chronic ...
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion for Verona Pharma and its potential blockbuster Ohtuvayre, a first-in-class ...
Verona Pharma's stock soars into record territory after buyout deal with Merck Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of ...
Methods/Approach: This retrospective study used CDC’s public mortality data from 1999 to 2020 to identify patients aged 35 and older with COPD (ICD-10 codes J40-J44) and those with OSA (ICD-10 code ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results